Navigation
The Company
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Contact Us
General Contact
For Healthcare Professionals
Careers
nab
-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Home
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Next Post
Previous Post
nab
-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
October 12, 2021
/
Publications
Like
this post!
Share
the Post
About
the Author
Related
Posts
Correlation of
nab
-sirolimus tumor drug levels and improved tumor suppression in
KRAS G12C
non-small cell lung cancer xenografts treated with
nab
-sirolimus in combination with KRAS inhibitors
Phase 2, multicenter, open-label basket trial of
nab
-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
or
TSC2
genes (PRECISION I)
Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer
Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology
Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update
Evaluation of
nab
-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines
A Phase 2, Open-Label, Single-Arm, Prospective, Multi-Center Study of
nab
-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Phase 2, multicenter, open-label basket trial of
nab
-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
or
TSC2
genes (PRECISION I)
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.